Open AccessWhat’s new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors
Author(s) -
Patricia C. Tsang,
Guoli Chen
Publication year - 2022
Publication title -
journal of pathology and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 27
eISSN - 2383-7845
pISSN - 2383-7837
DOI - 10.4132/jptm.2022.01.25
Subject(s) - medicine , biomarker , immune checkpoint , kidney cancer , immune system , molecular biomarkers , molecular pathology , cancer research , oncology , pathology , immunotherapy , cancer , immunology , biology , biochemistry , gene
Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.